Keywords: ucb, net, profit, down, belgian, drugmaker, full-year
UCB's 2007 net profit down 59% on M&A
Article | 10 March 2008
Belgian drugmaker UCB's full-year 2007 net profit dropped 59% year-on-year, to 160.0 million euros ($107.9 million), on charges related to last year's integration of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
